Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Conference Proceedings
  • Disease Areas
  • Other Medical News
  • Media
    • Podcast
    • Video
    • Education
  • About
    • Conference Proceedings
    • Vacancies

Tag: Brentuximab vedotin

First-line nivolumab-AVD improves PFS both in adult and paediatric patients with advanced Hodgkin lymphoma

Presented By
Prof. Alex Herrera, City of Hope Medical Center, CA, USA
Trial
Phase 3, SWOG S1826
Conference
ASCO 2023

1 August, 2023 12:38

Next-generation cell therapies for cancer: CAR-NK cells

Presented By
Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA
Conference
EBMT 2023

15 June, 2023 17:20

Novel drugs and strategies around ASCT for Hodgkin lymphoma

Presented By
Dr Anna Sureda, Catalan Institute of Oncology, Spain
Conference
EBMT 2023

15 June, 2023 17:15

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By
Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium
Trial
CheckMate 205; KEYNOTE-087
Conference
EHA 2021

5 August, 2021 12:26

Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma

Presented By
Prof. Pier Luigi Zinzani, University of Bologna, Italy
Trial
Phase 3, KEYNOTE-204
Conference
EHA 2020

9 September, 2020 12:38

Nivolumab/brentuximab vedotin in R/R HL: good CMR rates

Presented By
Prof. Christine Mauz-Körholz, Justus-Liebig-Universität Gießen, Germany
Trial
Phase 2, Checkmate 744
Conference
EHA 2020

28 August, 2020 12:09

Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma

Presented By
Dr Steven Horwitz , Memorial Sloan Kettering Cancer Center, USA
Trial
Phase 3, ECHELON-1
Conference
EHA 2019

9 August, 2019 20:49
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy